Healthcare provider profile · identity verified

Ernest Michael Josef, MD

Family Practice · ENOLA, PA · NPI 1902865314

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	377	115
Lisinopril	Lisinopril	219	62
Rosuvastatin Calcium	Rosuvastatin Calcium	180	50
Levothyroxine Sodium	Levothyroxine Sodium	165	43
Amlodipine Besylate	Amlodipine Besylate	163	51
Pantoprazole Sodium	Pantoprazole Sodium	136	40
Simvastatin	Simvastatin	116	36
Metoprolol Succinate	Metoprolol Succinate	111	37
Hydrochlorothiazide	Hydrochlorothiazide	103	33
Lorazepam	Lorazepam	95	22
Escitalopram Oxalate	Escitalopram Oxalate	93	27
Metformin Hcl Er	Metformin Hcl	89	28
Omeprazole	Omeprazole	88	25
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	81	23
Metformin Hcl	Metformin Hcl	74	21
Tamsulosin Hcl	Tamsulosin Hcl	74	22
Gabapentin	Gabapentin	71	18
Pioglitazone Hcl	Pioglitazone Hcl	62	19
Allopurinol	Allopurinol	57	13
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	56	55
Jardiance	Empagliflozin	56	13
Furosemide	Furosemide	55	17
Losartan Potassium	Losartan Potassium	55	18
Metoprolol Tartrate	Metoprolol Tartrate	55	12
Ozempic	Semaglutide	54	13
Trazodone Hcl	Trazodone Hcl	52	17
Eliquis	Apixaban	50	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	50	42
Tramadol Hcl	Tramadol Hcl	49	16
Glimepiride	Glimepiride	48	14
Zolpidem Tartrate	Zolpidem Tartrate	48	suppressed
Sertraline Hcl	Sertraline Hcl	46	15
Fluticasone Propionate	Fluticasone Propionate	45	15
Bupropion Xl	Bupropion Hcl	44	suppressed
Meloxicam	Meloxicam	42	14
Prednisone	Prednisone	42	33
Finasteride	Finasteride	41	13
Xarelto	Rivaroxaban	36	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	34	suppressed
Potassium Chloride	Potassium Chloride	34	suppressed
Atenolol	Atenolol	33	suppressed
Pravastatin Sodium	Pravastatin Sodium	33	11
Ezetimibe	Ezetimibe	32	suppressed
Irbesartan	Irbesartan	32	suppressed
Mirtazapine	Mirtazapine	32	11
Synthroid	Levothyroxine Sodium	32	suppressed
Trulicity	Dulaglutide	32	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	31	16
Duloxetine Hcl	Duloxetine Hcl	31	suppressed
Famotidine	Famotidine	29	suppressed
Carvedilol	Carvedilol	28	11
Cefdinir	Cefdinir	27	26
Doxazosin Mesylate	Doxazosin Mesylate	26	suppressed
Glipizide Er	Glipizide	25	suppressed
Nifedipine Er	Nifedipine	25	suppressed
Methylprednisolone	Methylprednisolone	24	22
Triamcinolone Acetonide	Triamcinolone Acetonide	23	13
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	22	suppressed
Midodrine Hcl	Midodrine Hcl	22	suppressed
Montelukast Sodium	Montelukast Sodium	22	suppressed
Citalopram Hbr	Citalopram Hydrobromide	20	suppressed
Clopidogrel	Clopidogrel Bisulfate	20	suppressed
Ketoconazole	Ketoconazole	20	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	20	suppressed
Diazepam	Diazepam	19	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	18	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	18	suppressed
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Rybelsus	Semaglutide	18	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	17	15
Clindamycin Hcl	Clindamycin Hcl	17	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	17	suppressed
Solifenacin Succinate	Solifenacin Succinate	17	suppressed
Valsartan	Valsartan	17	suppressed
Benazepril Hcl	Benazepril Hcl	16	suppressed
Diclofenac Sodium	Diclofenac Sodium	16	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	16	12
Labetalol Hcl	Labetalol Hcl	16	suppressed
Metronidazole	Metronidazole	16	suppressed
Donepezil Hcl	Donepezil Hcl	15	suppressed
Amiodarone Hcl	Amiodarone Hcl	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Fenofibrate	Fenofibrate,micronized	14	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	suppressed
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	14	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	13	suppressed
Enalapril Maleate	Enalapril Maleate	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Repaglinide	Repaglinide	13	suppressed
Risedronate Sodium	Risedronate Sodium	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Cephalexin	Cephalexin	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Oxycodone Hcl	Oxycodone Hcl	12	suppressed
Oxycontin	Oxycodone Hcl	12	suppressed
Spiriva Respimat	Tiotropium Bromide	12	suppressed
Telmisartan	Telmisartan	12	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	12	suppressed
Alprazolam	Alprazolam	11	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Azithromycin	Azithromycin	11	suppressed
Bumetanide	Bumetanide	11	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Fluocinonide	Fluocinonide	11	suppressed
Humalog	Insulin Lispro	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error